On behalf of the ASTCT Committee on Education, we are pleased to continue our monthly self-directed learning quiz "Basic Principles and Practices of Hematopoietic Cell Transplantation and Cell Therapy – Question and Answer Approach” for fellows in training, highlighting HCT and cell therapy topics. Answers to each question appear with evidence-based “non-exhaustive” peer-review commentary. Our aim is to provide you with a credible and freely available educational resource. Questions generated and reviewed by Syed Abutalib, MD, Amrita Krishnan, MD, and William A. Wood, MD.

Question Title

* 1. ELIANA study1- Tisagenlecleucel in children and young adults with B-cell acute lymphoblastic leukemia: Which statement about neurotoxicity is CORRECT?

Question Title

* 2. ELIANA study1- Tisagenlecleucel in children and young adults with B-cell acute lymphoblastic leukemia: Which of the following statement(s) with regards to development and management of B cell aplasia and hypogammaglobulinemia is CORRECT

Question Title

* 3. Approximately, what proportions of patients develop infections within the first month after CAR-T therapy despite antimicrobial prophylaxis?

Question Title

* 4. Which of the following statements about results from ZUMA-16 study -axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma- is CORRECT?

Question Title

* 5. ZUMA-1 study6 - axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. What proportions of patients who received axicabtagene ciloleucel experienced grade 3 or higher adverse events?

T